Recent Comments

Comment RSS

Leishmaniasis News and Research RSS Feed - Leishmaniasis News and Research

Leishmaniasis is a parasitic disease transmitted by the bite of infected sand flies. It is found in nearly 88 countries, from rain forests in Central and South America to deserts in the Middle East and west Asia. Some cases of the disease have also appeared in Mexico and Texas.

Leishmaniasis takes several different forms, including the most common cutaneous leishmaniasis, which causes skin sores, and the more severe visceral leishmaniasis, which affects internal organs such as the spleen, liver, and bone marrow. The World Health Organization (WHO) estimates that there are 1.5 million new cases of cutaneous leishmaniasis and 500,000 new cases of visceral leishmaniasis in the world each year.

Pfizer,DNDi partner to Identify NTD drugs; Sanofi-Aventis, medicines for malaria launch drug study

19. November 2009 22:17
Pfizer and the Drugs for Neglected Diseases Initiative (DNDi) on Wednesday announced plans to team up in an effort to identify new drug candidates for the treatment of three tropical diseases, the Associated Press/Business Week reports. The scientists will test the efficacy of Pfizer drug candidates against sleeping sickness, visceral leishmaniasis, and Chagas disease. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , ,

Pfizer and DNDi to battle against HAT, VL and Chagas disease

19. November 2009 02:03
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , ,

Researchers find compound that reverses type 1 myotonic dystrophy

7. November 2009 00:42
A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York. [More]

WHO, MSF highlight poor health situation in Southern Sudan

7. November 2009 00:15
Three quarters of people in South Sudan, which has a population of 8 million, do not have access to health care, and 10 percent of children there and in Darfur die before the age of 1, Mohammad Abdur Rab, the WHO's representative to Sudan, said Thursday, Reuters/ABC News reports. [More]

Posted in: Disease/Infection News | Healthcare News

Tags: , , , , ,

Scientists identify compounds that hold promise for treating parasitic infection

4. November 2009 03:44
Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases. [More]

Posted in: Medical Science News | Disease/Infection News

Tags: , , ,

Doctoral candidate sheds new light on the biology of Leishmania parasites

24. October 2009 05:39
Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated. [More]

Posted in: Medical Condition News | Disease/Infection News

Tags: , , ,

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

7. October 2009 10:01
Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization. [More]

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

6. October 2009 09:41
BioDelivery Sciences International, Inc. has received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , ,

Changing trends and developments in the global market for vaccines

25. September 2009 06:34
The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions. [More]

iCo Therapeutics, CPDD sign collaboration development agreement

25. September 2009 06:08
iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that the company has signed a collaboration development agreement with The Consortium for Parasitic Drug Development (CPDD) for the research and development of iCo's oral drug delivery technology for the treatment of neglected diseases such as leishmaniasis and trypanosomiasis. Initial funding of USD $182,930 will be provided for formulation optimization for tropical conditions. [More]

New report on DNA vaccine market

25. September 2009 05:09
Reportlinker.com announces that a new market research report is available in its catalogue. [More]

Clinton Global Initiative to raise awareness and funding for NTD control and elimination

24. September 2009 07:10
At the Clinton Global Initiative today, the Inter-American Development Bank joined with the Global Network for Neglected Tropical Diseases to announce their commitment to mobilize $30 million from the public and private sectors to raise awareness and funding for NTD control and elimination in the Americas, supported by technical assistance from the Pan American Health Organization, regional office of the World Health Organization for the Americas. [More]

BioDelivery Sciences International to integrate its Newark operations with company’s headquarters in Raleigh

2. September 2009 08:19
BioDelivery Sciences International, Inc. (Nasdaq: BDSI), today announced the consolidation of the company’s laboratory and other operations in Newark, New Jersey to the company’s headquarters in Raleigh, North Carolina. BDSI will vacate its Newark facility by September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Gates Foundation task force visits flooded Indian state

1. September 2009 02:13
The Bill & Melinda Gates Foundation recently sent an eight member task force, led by the foundation's country head Ashok Alexander, to the Indian state of Bihar, which has experienced significant flooding in many districts, PTI/Hindu reports (8/30). "With major rivers in spate, there is no let up in the overall flood situation in Bihar where 1.5 million people continue to reel under the deluge in 11 north Bihar districts," according to PTI (8/30). [More]

Posted in: Healthcare News

Tags: , ,

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

31. August 2009 07:52
The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass' proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential. [More]

Posted in: Device / Technology News

Tags: , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.